Should I buy or sell Ironwood Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IRWD shares. View IRWD analyst ratings or view top-rated stocks .

What is Ironwood Pharmaceuticals' stock price target for 2024?

5 analysts have issued 12-month target prices for Ironwood Pharmaceuticals' shares. Their IRWD share price targets range from $14.00 to $22.00. On average, they expect the company's share price to reach $19.80 in the next twelve months. This suggests a possible upside of 158.8% from the stock's current price. View analysts price targets for IRWD or view top-rated stocks among Wall Street analysts .

How have IRWD shares performed in 2024?

Ironwood Pharmaceuticals' stock was trading at $11.44 at the start of the year. Since then, IRWD shares have decreased by 33.1% and is now trading at $7.65. View the best growth stocks for 2024 here .

Are investors shorting Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 21,950,000 shares, an increase of 16.9% from the March 15th total of 18,770,000 shares. Based on an average trading volume of 4,770,000 shares, the days-to-cover ratio is currently 4.6 days. Approximately 14.5% of the company's shares are short sold. View Ironwood Pharmaceuticals' Short Interest .

When is Ironwood Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our IRWD earnings forecast .

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its earnings results on Thursday, November, 9th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.17 by $0.05. The biotechnology company had revenue of $113.74 million for the quarter, compared to analyst estimates of $112.90 million. Ironwood Pharmaceuticals had a negative trailing twelve-month return on equity of 185.45% and a negative net margin of 226.37%. The business's revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.28 EPS.

What ETFs hold Ironwood Pharmaceuticals' stock?

ETFs with the largest weight of Ironwood Pharmaceuticals (NASDAQ:IRWD) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV) , Virtus LifeSci Biotech Products ETF (BBP) , SPDR S&P Biotech ETF (XBI) , Invesco S&P SmallCap Health Care ETF (PSCH) and ALPS Medical Breakthroughs ETF (SBIO) . iShares U.S. Pharmaceuticals ETF (IHE) .

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $435.0 million-$455.0 million, compared to the consensus revenue estimate of $462.8 million.

What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO?

7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com . Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA) , Endologix (ELGX) , BlackRock (BLK) , Chipotle Mexican Grill (CMG) , NIC (EGOV) , Athabasca Oil (ATH) , Allergan (AGN) , Aegean Marine Petroleum Network (ANW) , Micron Technology (MU) and Starbucks (SBUX) .

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Hodges Capital Management Inc. (0.55%), Los Angeles Capital Management LLC (0.05%) and Grimes & Company Inc. (0.02%). Insiders that own company stock include Andrew Davis, Jason Rickard , Jon R Duane, Julie Mchugh , Mark G Currie , Marla L Kessler, Michael Shetzline , Minardo John, Ronald Silver , Sravan Kumar Emany, Thomas A Mccourt and Timothy M O'reilly. View institutional ownership trends .

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IRWD

Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis

→ [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad)

Free IRWD Stock Alerts

$7.65

-0.24 (-3.04%)

(As of 04/17/2024 ET)

Compare

Today's Range: $7.64
▼
$7.94
50-Day Range: $7.65
▼
$15.45
52-Week Range: $7.64
▼
$15.70

Volume: 2.40 million shs
Average Volume: 4.51 million shs
Market Capitalization: $1.20 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.80

Get Ironwood Pharmaceuticals alerts:

Ironwood Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 158.8% Upside
$19.80 Price Target
Short Interest: Bearish
14.48% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.94
Upright™ Environmental Score
News Sentiment: 0.48
Based on 3 Articles This Week
Insider Trading: Selling Shares
$4.16 M Sold Last Quarter
Proj. Earnings Growth: 19.72%
From $0.71 to $0.85 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.89 out of 5 stars

Medical Sector

194th out of 913 stocks

Pharmaceutical Preparations Industry

67th out of 397 stocks

3.5

Analyst's Opinion

Consensus Rating
Ironwood Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Ironwood Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
14.48% of the float of Ironwood Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Ironwood Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Ironwood Pharmaceuticals has recently increased by 16.94%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Ironwood Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Ironwood Pharmaceuticals does not have a long track record of dividend growth.

3.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Ironwood Pharmaceuticals has received a 39.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Linaclotide" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Ironwood Pharmaceuticals is -2.94.

1.4

News and Social Media Coverage

News Sentiment
Ironwood Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Ironwood Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 5 people have searched for IRWD on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ironwood Pharmaceuticals insiders have sold 2,493.59% more of their company's stock than they have bought. Specifically, they have bought $160,420.00 in company stock and sold $4,160,642.00 in company stock.
Percentage Held by Insiders
13.10% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Ironwood Pharmaceuticals are expected to grow by 19.72% in the coming year, from $0.71 to $0.85 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ironwood Pharmaceuticals is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ironwood Pharmaceuticals is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

IRWD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IRWD Stock News Headlines

April 16, 2024 | americanbankingnews.com

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Sees Large Increase in Short Interest

April 1, 2024 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Ironwood Pharma (IRWD)

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 28, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Ironwood Pharma (IRWD)

March 28, 2024 | businesswire.com

Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

March 20, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - IRWD

March 16, 2024 | msn.com

Ironwood Pharmaceuticals (NASDAQ:IRWD): Analysts Stay Bullish Despite Recent Stock Plunge

March 13, 2024 | finance.yahoo.com

It’s Time! 3 Failing Biotech Stocks to Sell Right Now

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 5, 2024 | investorplace.com

It's Time! 3 Failing Biotech Stocks to Sell Right Now

March 3, 2024 | finance.yahoo.com

IRWD Mar 2024 5.000 put

March 1, 2024 | msn.com

Ironwood plunges nearly 40% after SBS trial misses secondary goals

March 1, 2024 | reuters.com

Ironwood's bowel disease drug meets main goal of late-stage study

February 29, 2024 | markets.businessinsider.com

Ironwood Pharmaceuticals: Strong Buy Rating on LINZESS Performance and Apraglutide Market Potential

February 29, 2024 | finance.yahoo.com

Ironwood Pharmaceuticals Ran Up 32% Over Two Months — And Just Lost It All

February 29, 2024 | reuters.com

Ironwood says bowel disease treatment meets main goal in late-stage trial

February 29, 2024 | markets.businessinsider.com

Ironwood Pharma: Apraglutide Trial Meets Primary Goal, But Some Secondary Goals Not Met; Stock Dips

February 29, 2024 | msn.com

Why Is Ironwood Pharmaceuticals (IRWD) Stock Down 27% Today?

February 29, 2024 | finance.yahoo.com

Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

February 26, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC), AMN Healthcare Services (AMN) and Ironwood Pharma (IRWD)

February 23, 2024 | businesswire.com

Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference

February 17, 2024 | finance.yahoo.com

Ironwood Pharmaceuticals Full Year 2023 Earnings: EPS Misses Expectations

February 16, 2024 | finance.yahoo.com

Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally

February 15, 2024 | markets.businessinsider.com

Ironwood Pharmaceuticals Receives ‘Buy’ Rating from Analyst Amid Strong Performance and Promising Drug Pipeline

February 15, 2024 | msn.com

Ironwood Pharmaceuticals reports mixed Q4 results; initiates FY24 outlook

February 15, 2024 | finance.yahoo.com

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

February 15, 2024 | businesswire.com

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

See More Headlines

Receive IRWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 4/17/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:IRWD
CUSIP: 46333X10
CIK: 1446847
Web: www.ironwoodpharma.com
Phone: (617) 621-7722
Fax: 617-494-0480
Employees: 267
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $19.80
High Stock Price Target: $22.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +158.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 10.77
P/E Growth: N/A
Net Income: $-1,002,240,000.00
Net Margins: -226.37%
Pretax Margin: -214.14%
Return on Equity: -185.45%
Return on Assets: 21.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.84
Quick Ratio: 0.84

Sales & Book Value

Annual Sales: $442.73 million
Price / Sales: 2.70
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.21) per share
Price / Book: -3.46

Miscellaneous

Outstanding Shares: 156,530,000
Free Float: 136,024,000
Market Cap: $1.20 billion
Optionable: Optionable
Beta: 0.55

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Ms. Julie H. McHugh (Age 60)
Executive Chairman of the Board
Comp: $95k
Mr. Thomas A. McCourt (Age 67)
CEO & Director
Comp: $1.42M
Mr. Sravan Kumar Emany (Age 45)
Senior VP, Principal Financial Officer & CFO
Comp: $712.36k
Mr. John Minardo (Age 47)
Senior VP, Chief Legal Officer & Secretary
Comp: $675.88k
Dr. Michael Shetzline M.D. (Age 64)
Ph.D., Chief Medical Officer, Senior VP and Head of Research & Drug Development
Comp: $837.74k
Mr. Ronald Silver (Age 41)
Corporate Controller & Principal Accounting Officer
Mr. Marcel Moulaison
Vice President of Technical Operations
Greg Martini
Vice President of Strategic Finance & Investor Relations
Ms. Beth Calitri
Head of Corporate Communications & Media Relations
Mr. Mike Nanfito
Vice President of Sales & Sales Excellence

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IRWD Stock Analysis - Frequently Asked Questions

Should I buy or sell Ironwood Pharmaceuticals stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IRWD shares.
View IRWD analyst ratings or view top-rated stocks.
What is Ironwood Pharmaceuticals' stock price target for 2024?: 5 analysts have issued 12-month target prices for Ironwood Pharmaceuticals' shares. Their IRWD share price targets range from $14.00 to $22.00. On average, they expect the company's share price to reach $19.80 in the next twelve months. This suggests a possible upside of 158.8% from the stock's current price.
View analysts price targets for IRWD or view top-rated stocks among Wall Street analysts.
How have IRWD shares performed in 2024?: Ironwood Pharmaceuticals' stock was trading at $11.44 at the start of the year. Since then, IRWD shares have decreased by 33.1% and is now trading at $7.65.
View the best growth stocks for 2024 here.
Are investors shorting Ironwood Pharmaceuticals?: Ironwood Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 21,950,000 shares, an increase of 16.9% from the March 15th total of 18,770,000 shares. Based on an average trading volume of 4,770,000 shares, the days-to-cover ratio is currently 4.6 days. Approximately 14.5% of the company's shares are short sold.
View Ironwood Pharmaceuticals' Short Interest.
When is Ironwood Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our IRWD earnings forecast.
How were Ironwood Pharmaceuticals' earnings last quarter?: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its earnings results on Thursday, November, 9th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.17 by $0.05. The biotechnology company had revenue of $113.74 million for the quarter, compared to analyst estimates of $112.90 million. Ironwood Pharmaceuticals had a negative trailing twelve-month return on equity of 185.45% and a negative net margin of 226.37%. The business's revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.28 EPS.

What ETFs hold Ironwood Pharmaceuticals' stock?: ETFs with the largest weight of Ironwood Pharmaceuticals (NASDAQ:IRWD) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap Health Care ETF (PSCH) and ALPS Medical Breakthroughs ETF (SBIO).iShares U.S. Pharmaceuticals ETF (IHE).
What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?: Ironwood Pharmaceuticals updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $435.0 million-$455.0 million, compared to the consensus revenue estimate of $462.8 million.
What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO?: 7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Ironwood Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).
Who are Ironwood Pharmaceuticals' major shareholders?: Ironwood Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Hodges Capital Management Inc. (0.55%), Los Angeles Capital Management LLC (0.05%) and Grimes & Company Inc. (0.02%). Insiders that own company stock include Andrew Davis, Jason Rickard, Jon R Duane, Julie Mchugh, Mark G Currie, Marla L Kessler, Michael Shetzline, Minardo John, Ronald Silver, Sravan Kumar Emany, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends.
How do I buy shares of Ironwood Pharmaceuticals?: Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IRWD) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis

Ironwood Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD)

IRWD Stock Price History

IRWD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IRWD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™